Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CIGB IL-1 inhibitor
- Development stage
- Preclinical
- Lead developer
- Center for Genetic Engineering and Biotechnology
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Intravenous
01
Overview
CIGB IL-1 inhibitor is a recombinant biopharmaceutical candidate developed by the Cuban Center for Genetic Engineering and Biotechnology (CIGB). It functions as a recombinant human interleukin-1 receptor antagonist (rhIL-1ra), specifically designed to target and bind to the interleukin-1 receptor type I (IL-1RI). By competitively occupying the IL-1RI binding site, the drug prevents the pro-inflammatory cytokines IL-1α and IL-1β from initiating their signaling cascades. This mechanism is intended to suppress the chronic inflammation and tissue destruction characteristic of rheumatoid arthritis and to modulate the tumor microenvironment in various cancers, where IL-1 signaling is known to promote tumor growth, angiogenesis, and metastasis. The project is part of CIGB's strategic portfolio focusing on autoimmune diseases and oncology.
- Other names
- Interleukin-1 inhibitor (CIGB)Recombinant human IL-1 receptor antagonist (CIGB)rhIL-1rarhIL1rarhIL 1ra
02
Targets
IL1R1 (Interleukin-1 Receptor Type 1)IL1R2 (Interleukin-1 receptor type II)
Beyond the preview
Go deeper on CIGB IL-1 inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CIGB IL-1 inhibitor.